Hetty E. Carraway, MD

Closing out their discussion, Drs Hetty Carraway and Eytan M. Stein highlight an ongoing clinical trial investigating a triplet therapy for AML.

Dr Stein explains clinical trial data on the use of magrolimab plus azacitidine for patients with TP53-mutated AML.

Dr Carraway highlights some of the most urgent unmet needs for patients with higher-risk MDS.

Eytan M. Stein, MD, discusses how to treat patients with MDS who have IDH or TP53 mutations, and whether there is a role for targeted therapy in this patient population.

Dr Hetty Carraway muses on whether magrolimab plus azacitadine will be used as a standard treatment for higher-risk MDS in the future.

Drs Stein and Carraway explain the rationale for a magrolimab and azacitidine combination treatment for patients with higher-risk MDS with supporting data from 2 clinical trials.

Key opinion leaders describe the role of hypomethylating agents in treating higher-risk MDS and the treatment options after HMA failure.

Hetty Carraway, MD, illustrates the role of allogenic stem cell transplant in MDS and the criteria used to determine a patient’s eligibility.

Eytan M. Stein, MD, outlines the biggest factors to consider when choosing a treatment for higher-risk MDS, including the differences in quality-of-life for patients.

Dr Hetty Carraway reviews the available treatment options for patients with higher-risk MDS, and the biggest challenges of treatment.

Experts explain the treatment goals for patients with MDS, and discusses the role of molecular testing in patients with MDS.

Dr Eytan M Stein breaks down how patients with MDS are risk-stratified, and how the clinical outcomes differ between risk groups.

Hetty Carraway, MD, describes how MDS differs from acute myeloid leukemia (AML), and the percentage of patients who progress to AML from MDS.

Eytan M. Stein, MD, provides an overview of myelodysplastic syndrome, including risk factors, symptoms, and diagnosis.

Eytan Stein, MD and Hetty Carraway, MD, wrap up their discussion with a review of the unmet needs in AML treatment and exciting therapies in the pipeline.

Hetty Carraway, MD, explains the importance of bone marrow biopsies in patients with AML receiving treatment with venetoclax + azacitidine.

Hetty Carraway, MD and Eytan Stein, MD, discuss the appropriate strategies for the management of cytopenias in patients with AML on venetoclax + azacitidine treatment.

Eytan Stein, MD, presents the case of an 81-year-old patient with AML who is unfit for intensive induction therapy for discussion.

Hetty Carraway, MD, highlights the role of venetoclax + azacitidine in the treatment of patients with acute myeloid leukemia who are unfit for intensive induction therapy.

Eytan Stein, MD, continues the discussion of AML treatments with a look at the options for patients with AML and mutations.

Eytan Stein, MD, reviews the available treatment options for patients with secondary AML or AML with myelodysplasia-related changes.

Hetty Carraway, MD, describes the criteria used to determine if a patient with newly-diagnosed acute myeloid leukemia is suitable for intensive induction therapy.

Eytan Stein, MD, provides an overview of the frontline treatment options currently available for acute myeloid leukemia.

Experts explain the goals of treatment for acute myeloid leukemia and the challenges presented.

Hetty Carraway, MD, discusses the process of diagnosing acute myeloid leukemia and its clinical subtypes.

Eytan Stein, MD, provides a brief overview of acute myeloid leukemia.